Lotus Eye Hospital and Institute Limited (LOTUSEYE:NSE) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Lotus Eye Hospital and Institute Limited stock forecast from 0 analysts, the average analyst target price for Lotus Eye Hospital and Institute Limited is not available over the next 12 months. Lotus Eye Hospital and Institute Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Lotus Eye Hospital and Institute Limited is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Lotus Eye Hospital and Institute Limited’s stock price was INR 59.35. Lotus Eye Hospital and Institute Limited’s stock price has changed by -2.22% over the past week, -0.67% over the past month and -5.42% over the last year.
No recent analyst target price found for Lotus Eye Hospital and Institute Limited
No recent average analyst rating found for Lotus Eye Hospital and Institute Limited
Company Overview Lotus Eye Hospital and Institute Limited
Lotus Eye Hospital and Institute Limited, an eye hospital, provides eye care and related services in India. It offers services in the areas of cataract, refractive surgery, retinal disease and diabetic eye care, uvea and ocular inflammation, cornea infections, glaucoma, computer vision syndrome, orbit and oculoplasty, neuro ophthalmology, ocular prosthesis, binocular vision, keratoconus, and zyoptix ultimate, as well as operates an eye bank. In addition, it offers various optical fellowship courses, as well as DNB training services. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was incorporated in 1997 and is based in Coimbatore, India. Read Less
Lotus Eye Hospital and Institute Limited, an eye hospital, provides eye care and related services in India. It offers services in the areas of cataract, refractive surgery, retinal disease and diabetic eye care, uvea and ocular inflammation, cornea infections, glaucoma, computer ...Read More
Frequently Asked Questions About Lotus Eye Hospital and Institute Limited (LOTUSEYE:NSE) Stock
Stock Target Advisor's fundamental analysis for Lotus Eye Hospital and Institute Limited's stock is Neutral.
LOTUSEYE:NSE stock's dividend yield is 0.87%.
Our analysis grades LOTUSEYE:NSE stock's dividend yield at B+. This means that LOTUSEYE:NSE stock's dividend yield is above 88% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this LOTUSEYE:NSE may be a good dividend stock for its sector.
Unfortunately we do not have enough data on LOTUSEYE:NSE's stock to indicate what its average analyst target is.
LOTUSEYE:NSE stock's Price/Earning ratio is 32.74.
Our analysis grades LOTUSEYE:NSE stock's Price / Earning ratio at B. This means that LOTUSEYE:NSE stock's Price/Earning ratio is above 14% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this LOTUSEYE:NSE may be undervalued for its sector.
The last closing price of LOTUSEYE:NSE's stock was INR 59.35.
The most recent market capitalization for LOTUSEYE:NSE is INR 1.16B.
Unfortunately we do not have enough analyst data on LOTUSEYE:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Lotus Eye Hospital and Institute Limited's stock.
As per our most recent records Lotus Eye Hospital and Institute Limited has 313 Employees.
Lotus Eye Hospital and Institute Limited's registered address is S.F. No. 770/12, Avinashi Road, Coimbatore, India, 641014.
You can get more information about it from Lotus Eye Hospital and Institute Limited's website at https://www.lotuseye.org.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LOTUSEYE:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
